Literature DB >> 32594382

Mesenchymal Stem Cells Ameliorate Cuprizone-Induced Demyelination by Targeting Oxidative Stress and Mitochondrial Dysfunction.

Elham Shiri1, Parichehr Pasbakhsh1, Maryam Borhani-Haghighi1, Zohreh Alizadeh2, Saied Nekoonam1, Sina Mojaverrostami1, Vahid Pirhajati Mahabadi3, Ali Mehdi4, Kazem Zibara5, Iraj Ragerdi Kashani6.   

Abstract

Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system. The main causes of MS disease progression, demyelination, and tissue damage are oxidative stress and mitochondrial dysfunction. Hence, the latter are considered as important therapeutic targets. Recent studies have demonstrated that mesenchymal stem cells (MSCs) possess antioxidative properties and are able to target mitochondrial dysfunction. Therefore, we investigated the effect of transplanting Wharton's jelly-derived MSCs in a demyelination mouse model of MS in which mice were fed cuprizone (CPZ) for 12 weeks. CPZ is a copper chelator that impairs the activity of cytochrome oxidase, decreases oxidative phosphorylation, and produces degenerative changes in oligodendrocytes, leading to toxic demyelination similar to those found in MS patients. Results showed that MSCs caused a significant increase in the percentage of myelinated areas and in the number of myelinated fibers in the corpus callosum of the CPZ + MSC group, compared to the CPZ group, as assessed by Luxol fast blue staining and transmission electron microscopy. In addition, transplantation of MSCs significantly increased the number of oligodendrocytes while decreasing astrogliosis and microgliosis in the corpus callosum of the CPZ + MSC group, evaluated by immunofluorescence. Moreover, the mechanism by which MSCs exert these physiological effects was found to be through abolishing the effect of CPZ on oxidative stress markers and mitochondrial dysfunction. Indeed, malondialdehyde significantly decreased while glutathione and superoxide dismutase significantly increased in CPZ + MSC mice group, in comparison witth the CPZ group alone. Furthermore, cell therapy with MSC transplantation increased the expression levels of mitochondrial biogenesis transcripts PGC1α, NRF1, MFN2, and TFAM. In summary, these results demonstrate that MSCs may attenuate MS by promoting an antioxidant response, reducing oxidative stress, and improving mitochondrial homeostasis.
© 2020. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cuprizone; Mesenchymal stem cells; Mitochondria; Multiple sclerosis; Myelination; Oxidative stress

Mesh:

Substances:

Year:  2020        PMID: 32594382     DOI: 10.1007/s10571-020-00910-6

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  49 in total

1.  Fragmented mitochondria are sensitized to Bax insertion and activation during apoptosis.

Authors:  Craig Brooks; Sung-Gyu Cho; Cong-Yi Wang; Tianxin Yang; Zheng Dong
Journal:  Am J Physiol Cell Physiol       Date:  2010-12-15       Impact factor: 4.249

2.  Effect of mesenchymal stem cells on glial cells population in cuprizone induced demyelination model.

Authors:  Shirin Barati; Iraj Ragerdi Kashani; Fatemeh Tahmasebi; Soraya Mehrabi; Mohammad Taghi Joghataei
Journal:  Neuropeptides       Date:  2019-04-13       Impact factor: 3.286

3.  Myelin debris regulates inflammatory responses in an experimental demyelination animal model and multiple sclerosis lesions.

Authors:  Tim Clarner; Felix Diederichs; Katharina Berger; Bernd Denecke; Lin Gan; Paul van der Valk; Cordian Beyer; Sandra Amor; Markus Kipp
Journal:  Glia       Date:  2012-06-11       Impact factor: 7.452

4.  Multipotent mesenchymal stromal cells attenuate chronic inflammation and injury-induced sensitivity to mechanical stimuli in experimental spinal cord injury.

Authors:  M Birdsall Abrams; Cecilia Dominguez; Karin Pernold; Roxanne Reger; Zsuzsanna Wiesenfeld-Hallin; Lars Olson; Darwin Prockop
Journal:  Restor Neurol Neurosci       Date:  2009       Impact factor: 2.406

5.  Mitochondrial transcription factor A regulates mtDNA copy number in mammals.

Authors:  Mats I Ekstrand; Maria Falkenberg; Anja Rantanen; Chan Bae Park; Martina Gaspari; Kjell Hultenby; Pierre Rustin; Claes M Gustafsson; Nils-Göran Larsson
Journal:  Hum Mol Genet       Date:  2004-03-11       Impact factor: 6.150

Review 6.  Stem cells for the treatment of neurodegenerative diseases.

Authors:  Elise Dantuma; Stephanie Merchant; Kiminobu Sugaya
Journal:  Stem Cell Res Ther       Date:  2010-12-10       Impact factor: 6.832

Review 7.  Immunoregulation by mesenchymal stem cells: biological aspects and clinical applications.

Authors:  Marta E Castro-Manrreza; Juan J Montesinos
Journal:  J Immunol Res       Date:  2015-04-19       Impact factor: 4.818

8.  Antioxidant Effects of Bone Marrow Mesenchymal Stem Cell against Carbon Tetrachloride-Induced Oxidative Damage in Rat Livers.

Authors:  M Ayatollahi; Z Hesami; A Jamshidzadeh; B Gramizadeh
Journal:  Int J Organ Transplant Med       Date:  2014

9.  Intraventricular injections of mesenchymal stem cells activate endogenous functional remyelination in a chronic demyelinating murine model.

Authors:  P Cruz-Martinez; S González-Granero; M M Molina-Navarro; J Pacheco-Torres; J M García-Verdugo; E Geijo-Barrientos; J Jones; S Martinez
Journal:  Cell Death Dis       Date:  2016-05-12       Impact factor: 8.469

10.  The Effect of Human Umbilical Cord Mesenchymal Stromal Cells in Protection of Dopaminergic Neurons from Apoptosis by Reducing Oxidative Stress in the Early Stage of a 6-OHDA-Induced Parkinson's Disease Model.

Authors:  Heng Chi; Yunqian Guan; Fengyan Li; Zhiguo Chen
Journal:  Cell Transplant       Date:  2019-11-28       Impact factor: 4.064

View more
  8 in total

Review 1.  The mechanistic target of rapamycin as a regulator of metabolic function in oligodendroglia during remyelination.

Authors:  Marie L Mather; Marisa A Jeffries; Teresa L Wood
Journal:  Curr Opin Pharmacol       Date:  2022-03-01       Impact factor: 5.547

2.  Nebivolol elicits a neuroprotective effect in the cuprizone model of multiple sclerosis in mice: emphasis on M1/M2 polarization and inhibition of NLRP3 inflammasome activation.

Authors:  Antoinette G Naeem; Reem N El-Naga; Haidy E Michel
Journal:  Inflammopharmacology       Date:  2022-08-10       Impact factor: 5.093

3.  The Efficacy of Mesenchymal Stem Cell Therapies in Rodent Models of Multiple Sclerosis: An Updated Systematic Review and Meta-Analysis.

Authors:  Jialin He; Yan Huang; Jianyang Liu; Ziwei Lan; Xiangqi Tang; Zhiping Hu
Journal:  Front Immunol       Date:  2021-08-26       Impact factor: 7.561

4.  Integrating Lipidomics and Transcriptomics Reveals the Crosstalk Between Oxidative Stress and Neuroinflammation in Central Nervous System Demyelination.

Authors:  Zhi-Jie Zhao; Rui-Zhe Zheng; Xiao-Jing Wang; Tong-Qi Li; Xiao-Hua Dong; Chang-Yi Zhao; Xin-Yuan Li
Journal:  Front Aging Neurosci       Date:  2022-04-25       Impact factor: 5.750

Review 5.  Prohibitins: A Key Link between Mitochondria and Nervous System Diseases.

Authors:  Tianlin Jiang; Jiahua Wang; Chao Li; Guiyun Cao; Xiaohong Wang
Journal:  Oxid Med Cell Longev       Date:  2022-07-08       Impact factor: 7.310

6.  A novel cell-free intrathecal approach with PRP for the treatment of spinal cord multiple sclerosis in cats.

Authors:  Mariam F Farid; Yara S Abouelela; Noha A E Yasin; Mohamed R Mousa; Marwa A Ibrahim; Abdelbary Prince; Hamdy Rizk
Journal:  Inflamm Regen       Date:  2022-10-14

Review 7.  Mesenchymal Stem Cells in Multiple Sclerosis: Recent Evidence from Pre-Clinical to Clinical Studies.

Authors:  Agnese Gugliandolo; Placido Bramanti; Emanuela Mazzon
Journal:  Int J Mol Sci       Date:  2020-11-17       Impact factor: 5.923

8.  Untargeted Metabolomic Profiling of Cuprizone-Induced Demyelination in Mouse Corpus Callosum by UPLC-Orbitrap/MS Reveals Potential Metabolic Biomarkers of CNS Demyelination Disorders.

Authors:  Zhijie Zhao; Tongqi Li; Xiaohua Dong; Xiaojing Wang; Zhongxiao Zhang; Changyi Zhao; Xueran Kang; Ruizhe Zheng; Xinyuan Li
Journal:  Oxid Med Cell Longev       Date:  2021-09-14       Impact factor: 6.543

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.